NASDAQ:ESPR

Esperion Therapeutics Stock Insider Trading

Healthcare > Drug Manufacturers - Specialty & Generic

Buy ESPR

*Your capital is at risk

$3.18

+0 (+0%)

At Close: Jul 14, 2026

Esperion Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -45.09. In total, the insiders bought 4.69M and sold 8.6M ESPR shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-45.09
● Buy	4.69M shares
● Sell	8.6M shares
42% Buy Activity Negligible or No Correlation
Sell Signal Medium Confidence Jul 13, 2026 Analysis Breakdown: Supported by a negative Insider Power Score of -45.09. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jul 13, 2026 Sell	Stock Option (right to buy) D-Return	Koenig Sheldon L. President And CEO	CEO / President	647 460 Value: $1.58M
Jul 13, 2026 Sell	Common Stock D-Return	Koenig Sheldon L. President And CEO	CEO / President	2 121 094 Value: $2K
Jul 13, 2026 Sell	Stock Option (right to buy) D-Return	Halladay Benjamin Chief Financial Officer	C-Suite Officer	221 270 Value: $539.9K
Jul 13, 2026 Sell	Stock Option (right to buy) D-Return	Looker Benjamin Chief Legal Officer	Officer	269 230 Value: $656.9K
Jul 13, 2026 Sell	Stock Option (right to buy) D-Return	Looker Benjamin Chief Legal Officer	Officer	201 000 Value: $301.5K
Jul 13, 2026 Sell	Stock Option (right to buy) D-Return	Looker Benjamin Chief Legal Officer	Officer	150 000 Value: $307.5K
Jul 13, 2026 Sell	Stock Option (right to buy) D-Return	Shepard Jay Director	Director	44 000 Value: $38.3K
Jul 13, 2026 Sell	Stock Option (right to buy) D-Return	Shepard Jay Director	Director	32 500 Value: $73.1K
Jul 13, 2026 Sell	Stock Option (right to buy) D-Return	Shepard Jay Director	Director	21 000 Value: $28.8K
Jul 13, 2026 Sell	Common Stock D-Return	Shepard Jay Director	Director	164 472 Value: $164
Jul 13, 2026 Sell	Stock Option (right to buy) D-Return	Carroll J Martin Director	Director	44 000 Value: $38.3K
Jul 13, 2026 Sell	Stock Option (right to buy) D-Return	Carroll J Martin Director	Director	32 500 Value: $73.1K
Jul 13, 2026 Sell	Stock Option (right to buy) D-Return	Carroll J Martin Director	Director	21 000 Value: $28.8K
Jul 13, 2026 Sell	Common Stock D-Return	Carroll J Martin Director	Director	177 523 Value: $178
Jul 13, 2026 Sell	Common Stock D-Return	Hoffman Robert E. Director	Director	85 153 Value: $85
Jul 13, 2026 Sell	Stock Option (right to buy) D-Return	Fischer Seth H. Z. Director	Director	32 500 Value: $73.1K
Jul 13, 2026 Sell	Stock Option (right to buy) D-Return	Hoffman Robert E. Director	Director	40 000 Value: $56.4K
Jul 13, 2026 Sell	Stock Option (right to buy) D-Return	Hoffman Robert E. Director	Director	7 040 Value: $6K
Jul 13, 2026 Sell	Common Stock D-Return	Fischer Seth H. Z. Director	Director	141 023 Value: $141
Jul 13, 2026 Sell	Stock Option (right to buy) D-Return	Fischer Seth H. Z. Director	Director	21 000 Value: $28.8K
Jul 13, 2026 Sell	Stock Option (right to buy) D-Return	Fischer Seth H. Z. Director	Director	44 000 Value: $38.3K
Jul 13, 2026 Sell	Common Stock D-Return	Thompson John Craig Director	Director	79 873 Value: $80
Jul 13, 2026 Sell	Stock Option (right to buy) D-Return	Thompson John Craig Director	Director	40 000 Value: $40.0K
Jul 13, 2026 Sell	Common Stock D-Return	Harlow John B. Jr. Chief Commercial Officer	Officer	424 536 Value: $425
Jul 13, 2026 Sell	Common Stock D-Return	Looker Benjamin Chief Legal Officer	Officer	667 524 Value: $668

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ESPERION THERAPEUTICS

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration a...

Read Full Profile Here